Figure 1.

Antibody responses to SARS-CoV-2 viral proteins among patients treated with bamlanivimab monotherapy, bamlanivimab and etesevimab together, and placebo. Least squares means ( ± SE) were plotted across visit days for different treatment groups. The full-length spike protein carries the D614G substitution. Titers against Spike-RBD E484Q not shown for cohort receiving bamlanivimab and etesevimab together as etesevimab binds to this mutant protein. The number of samples at each timepoint are outlined in Table 1 . RBD, Receptor binding domain; NCP, Nucleocapsid protein; NTD, N-terminal domain; SE, Standard error.